As drug-resistant pathogens are making many existing #antibiotics ineffective, how can we introduce new antibiotics in India responsibly?
Our Global IP Advisor @LMenghaney & our #AMR Pharmacist @Jasovsky_ answer in @down2earthindia#WAAW2024 🇮🇳
https://t.co/cfQ7zSMfcF
Despite the greater risk of antimicrobial resistance in low- and middle-income countries, experts say the focus of international agreements so far has been centered around the needs of high-income countries. https://t.co/MumjoFTp8v
Tomorrow, world leaders meet at the UN High level meeting #UNHLM on antimicrobial resistance to agree on a political declaration committing to respond to #AMR.
We urge them to take swift, bold action to translate this declaration into meaningful progress🧵
https://t.co/ZnApXe1HW1
The high costs of new antibiotics (up to 20-fold more expensive than older alternatives) for carbapenem-resistant Enterobacterales, MDR P. aeruginosa, and A. baumannii a significant barrier to accessibility in low-resource settings. #AMR#MSF https://t.co/eHHUvjkxBl
“[...] the #AMR HLM cannot be merely another forum for discussion. It must instead be a platform for commitment & accountability, where countries & global health actors take concrete steps on AMR.”
- Dušan Jasovský, MSF Access Campaign AMR Pharmacist.
https://t.co/yO4AQ8Pr8P
In our latest blog, Dr Jane Cunningham takes a close look at the importance of diagnostic testing in tackling #AntimicrobialResistance. W/ the UN High-Level Mtg on #AMR in Sep, we urge that people most impacted by AMR be at the centre of any solutions.
https://t.co/OqE5ZYvBMP
Ahead of the #UNHLM on #AMR, we call on govts to:
1. 🎯 Prioritise universal access to effective diagnostics & drugs. R&D of new antibiotics must target the most urgent global public health needs & have conditions making them affordable & accessible to all.
#AMR is a global concern & tackling it requires extensive collaboration & strong commitments.
As part of the prep for the #UNHLM on AMR in Sep, MSF’s Rep to the UN, Tara Newell, delivered the following statement with our recommendations.
🔗https://t.co/wcUyZA4lUD
We're pleased to host the #H20Summit at @WHO this year again.
I shared three priorities for our shared vision of #HealthForAll:
1) Continued political commitment at the highest level for global health;
2) Engagement with platforms, such as the @G20Partnership, that bring sectors together to discuss and share ideas and experiences on global health;
3) Sustainable financing for WHO.
My thanks to @hatice_beton and @AlanDonnelly57 for their leadership.
At #WHA77 we raised the issue of evidence asymmetry on #AMR between high-income and low-resource contexts➡️any independent evidence platform must engage CSOs and affected communities to address the needs of those most impacted by AMR and least equipped with relevant data #UN#HLM
At the 77th World Health Assembly this week, we’re calling for better access to health products for all people & improved pandemic prevention, preparedness & response.
Read our statements here👇🧵 #WHA77
https://t.co/hBy0JLrfKN
2️⃣ Ahead of the UN High-Level Mtg #UNHLM on #AntimicrobialResistance#AMR in Sep, govts must:
a. Make access to person-centred health care more equitable
b. Ensure AMR action plans prioritise low- & middle- income countries
c. Make AMR-related medical products accessible for all
Antibiogo is a FREE, office & open resource to support laboratory technicians 👨🔬👩🔬
Check out Nada Malou's presentation on it's capabilities!
#MSFSci
#AntimicrobialResistance is a global health threat. Today, MSF's Representative to the UN, Tara Newell, delivered the following statement with our recommendations to tackle #AMR, as part of the prep for the 2024 High-Level Meeting on AMR in Sept.
https://t.co/wcUyZA4TKb
In #MSFSci 2021, Dr Nada Malou presented Antibiogo to help microbiologists in low-resource settings tackle #AMR 🦠.
Since then, Antigiogo has had a massive impact, this is their story👇
Catch her at this year's #MSFSci!
➡️https://t.co/HsRfU5wfiW
We call on govts for 1. governance & financing mechanism to tackle #AMR in LMICs; 2. access to drugs, tests & vax by ⬆️ manufacturing, pooled procurement & R&D funding access conditions; 3. infection prevention, antimicrobial stewardship & lab capacity.
https://t.co/mwQjSxa5PU
Happy to meet with Dušan Jasovsky at Médecins Sans Frontières Geneva to discuss issues on AMR ahead of the upcoming High Level meeting in the UN in September